{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:31:19Z","timestamp":1768311079020,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,6]],"date-time":"2018-01-06T00:00:00Z","timestamp":1515196800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473138"],"award-info":[{"award-number":["81473138"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GD Frontier & KeyTechn. Innovation Program","award":["2015B010109004"],"award-info":[{"award-number":["2015B010109004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10822-017-0092-8","type":"journal-article","created":{"date-parts":[[2018,1,6]],"date-time":"2018-01-06T05:51:02Z","timestamp":1515217862000},"page":"347-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Discovering new PI3K\u03b1 inhibitors with a strategy of combining ligand-based and structure-based virtual screening"],"prefix":"10.1007","volume":"32","author":[{"given":"Miao","family":"Yu","sequence":"first","affiliation":[]},{"given":"Qiong","family":"Gu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-0337","authenticated-orcid":false,"given":"Jun","family":"Xu","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,1,6]]},"reference":[{"key":"92_CR1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M, Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen EE, Varner JA (2016) PI3Kgamma is a molecular switch that controls immune suppression. Nature 539:437\u2013442","journal-title":"Nature"},{"key":"92_CR2","doi-asserted-by":"crossref","first-page":"6443","DOI":"10.1128\/JVI.00214-16","volume":"90","author":"O Cojohari","year":"2016","unstructured":"Cojohari O, Peppenelli MA, Chan GC (2016) Human cytomegalovirus induces an atypical activation of akt to stimulate the survival of short-lived monocytes. J Virol 90:6443\u20136452","journal-title":"J Virol"},{"key":"92_CR3","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.bmc.2017.01.012","volume":"25","author":"MS Miller","year":"2017","unstructured":"Miller MS, Maheshwari S, McRobb FM, Kinzler KW, Amzel LM, Vogelstein B, Gabelli SB (2017) Identification of allosteric binding sites for PI3Kalpha oncogenic mutant specific inhibitor design. Bioorg Med Chem 25:1481\u20131486","journal-title":"Bioorg Med Chem"},{"key":"92_CR4","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","volume":"21","author":"BW Miller","year":"2015","unstructured":"Miller BW, Przepiorka D, de Claro RA, Lee K, Nie L, Simpson N, Gudi R, Saber H, Shord S, Bullock J, Marathe D, Mehrotra N, Hsieh LS, Ghosh D, Brown J, Kane RC, Justice R, Kaminskas E, Farrell AT, Pazdur R (2015) FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res 21:1525\u20131529","journal-title":"Clin Cancer Res"},{"key":"92_CR5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140\u2013156","journal-title":"Nat Rev Drug Discov"},{"key":"92_CR6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550\u2013562","journal-title":"Nat Rev Cancer"},{"key":"92_CR7","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","volume":"23","author":"DC Fingar","year":"2004","unstructured":"Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151\u20133171","journal-title":"Oncogene"},{"key":"92_CR8","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1038\/sj.onc.1210918","volume":"27","author":"A Denley","year":"2008","unstructured":"Denley A, Kang S, Karst U, Vogt PK (2008) Oncogenic signaling of class I PI3K isoforms. Oncogene 27:2561\u20132574","journal-title":"Oncogene"},{"key":"92_CR9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.coph.2008.08.004","volume":"8","author":"TA Yap","year":"2008","unstructured":"Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8:393\u2013412","journal-title":"Curr Opin Pharmacol"},{"key":"92_CR10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","volume":"10","author":"F Janku","year":"2011","unstructured":"Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors. Mol Cancer Ther 10:558\u2013565","journal-title":"Mol Cancer Ther"},{"key":"92_CR11","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1007\/s13277-016-4924-2","volume":"37","author":"E Dirican","year":"2016","unstructured":"Dirican E, Akkiprik M, Ozer A (2016) Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. Tumour Biol 37:7033\u20137045","journal-title":"Tumour Biol"},{"key":"92_CR12","doi-asserted-by":"crossref","first-page":"13153","DOI":"10.18632\/oncotarget.7549","volume":"7","author":"D Wang.","year":"2016","unstructured":"Wang. D, Wang. M, Jiang N, Zhang. Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu. P, Cheng H (2016) Effective use of PI3K inhibitor BKM120 and PARP inhibitor olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget 7:13153\u201313166","journal-title":"Oncotarget"},{"key":"92_CR13","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","volume":"68","author":"PJ Eichhorn","year":"2008","unstructured":"Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221\u20139230","journal-title":"Cancer Res"},{"key":"92_CR14","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","volume":"7","author":"SM Maira","year":"2008","unstructured":"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851\u20131863","journal-title":"Mol Cancer Ther"},{"key":"92_CR15","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","volume":"68","author":"V Serra","year":"2008","unstructured":"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J (2008) NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68:8022\u20138030","journal-title":"Cancer Res"},{"key":"92_CR16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hutt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M (2015) Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21:555\u2013559","journal-title":"Nat Med"},{"key":"92_CR17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","volume":"4","author":"JM Balko","year":"2014","unstructured":"Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sanchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gomez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL (2014) Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 4:232\u2013245","journal-title":"Cancer Discov"},{"key":"92_CR18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508:118\u2013122","journal-title":"Nature"},{"key":"92_CR19","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/2159-8290.CD-11-0046","volume":"1","author":"HW Cheung","year":"2011","unstructured":"Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Janne PA, Hahn WC (2011) Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 1:608\u2013625","journal-title":"Cancer Discov"},{"key":"92_CR20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nature14412","volume":"520","author":"A Mbengue","year":"2015","unstructured":"Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, Rizk SS, Njimoh DL, Ryan Y, Chotivanich K, Nguon C, Ghorbal M, Lopez-Rubio JJ, Pfrender M, Emrich S, Mohandas N, Dondorp AM, Wiest O, Haldar K (2015) A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520:683\u2013687","journal-title":"Nature"},{"key":"92_CR21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.cell.2013.04.023","volume":"153","author":"A Csibi","year":"2013","unstructured":"Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T, Henske EP, Haigis MC, Cantley LC, Stephanopoulos G, Yu J, Blenis J (2013) The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153:840\u2013854","journal-title":"Cell"},{"key":"92_CR22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/leu.2011.322","volume":"26","author":"G Fuka","year":"2012","unstructured":"Fuka G, Kantner HP, Grausenburger R, Inthal A, Bauer E, Krapf G, Kaindl U, Kauer M, Dworzak MN, Stoiber D, Haas OA, Panzer-Grumayer R (2012) Silencing of ETV6\/RUNX1 abrogates PI3K\/AKT\/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia 26:927\u2013933","journal-title":"Leukemia"},{"key":"92_CR23","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/emm.2014.127","volume":"47","author":"YW Yi","year":"2015","unstructured":"Yi YW, Kang HJ, Bae EJ, Oh S, Seong YS, Bae I (2015) beta-TrCP1 degradation is a novel action mechanism of PI3K\/mTOR inhibitors in triple-negative breast cancer cells. Exp Mol Med 47:e143","journal-title":"Exp Mol Med"},{"key":"92_CR24","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2014-11-610329","volume":"125","author":"MD Blunt","year":"2015","unstructured":"Blunt MD, Carter MJ, Larrayoz M, Smith LD, Aguilar-Hernandez M, Cox KL, Tipton T, Reynolds M, Murphy S, Lemm E, Dias S, Duncombe A, Strefford JC, Johnson PWM, Forconi F, Stevenson FK, Packham G, Cragg MS, Steele AJ (2015) The PI3K\/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E -TCL1 mouse model. Blood 125:4032\u20134041","journal-title":"Blood"},{"key":"92_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ml900028r","volume":"1","author":"SD Knight","year":"2010","unstructured":"Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, Donatelli CA, Luengo JI, Newlander KA, Parrish CA, Ridgers LH, Sarpong MA, Schmidt SJ, Van Aller GS, Carson JD, Diamond MA, Elkins PA, Gardiner CM, Garver E, Gilbert SA, Gontarek RR, Jackson JR, Kershner KL, Luo L, Raha K, Sherk CS, Sung CM, Sutton D, Tummino PJ, Wegrzyn RJ, Auger KR, Dhanak D (2010) Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett 1:39\u201343","journal-title":"ACS Med Chem Lett"},{"key":"92_CR26","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1158\/1535-7163.MCT-11-0185","volume":"10","author":"J Yuan","year":"2011","unstructured":"Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 10:2189\u20132199","journal-title":"Mol Cancer Ther"},{"key":"92_CR27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","volume":"15","author":"SY Yang","year":"2010","unstructured":"Yang SY (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15:444\u2013450","journal-title":"Drug Discov Today"},{"key":"92_CR28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11030-014-9543-5","volume":"18","author":"L Chen.","year":"2014","unstructured":"Chen. L, Wang L, Gu Q, Xu J (2014) An in silico protocol for indentifying mTOR inhibitors from natural products. Mol Divers 18:841\u2013852","journal-title":"Mol Divers"},{"key":"92_CR29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10916-009-9360-z","volume":"35","author":"V Jalali","year":"2011","unstructured":"Jalali V, Matash Borujerdi MR (2011) A unified architecture for biomedical search engines based on semantic web technologies. J Med Syst 35:237\u2013249","journal-title":"J Med Syst"},{"key":"92_CR30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10822-009-9260-9","volume":"23","author":"J Overington","year":"2009","unstructured":"Overington J (2009) ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr. J Comput Aided Mol Des 23:195\u2013198","journal-title":"J Comput Aided Mol Des"},{"key":"92_CR31","doi-asserted-by":"crossref","first-page":"D198","DOI":"10.1093\/nar\/gkl999","volume":"35","author":"T Liu","year":"2007","unstructured":"Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35:D198\u2013D201","journal-title":"Nucleic Acids Res"},{"key":"92_CR32","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1039\/C4MB00718B","volume":"11","author":"Y Li","year":"2015","unstructured":"Li Y, Wang L, Liu Z, Li C, Xu J, Gu Q, Xu J (2015) Predicting selective liver X receptor beta agonists using multiple machine learning methods. Mol Biosyst 11:1241\u20131250","journal-title":"Mol Biosyst"},{"key":"92_CR33","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger MM, Irwin MC,JJ, Shoichet BK (2012) Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem 55:6582\u20136594","journal-title":"J Med Chem"},{"key":"92_CR34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/bioinformatics\/16.5.412","volume":"16","author":"P Baldi","year":"2000","unstructured":"Baldi P, Brunek S, Chauvin Y et al (2000) Assessing the accuracy of prediction algorithms for classification: an overview. Bioinform Rev 16:412\u2013424","journal-title":"Bioinform Rev"},{"key":"92_CR35","doi-asserted-by":"crossref","unstructured":"Bar A, Rokach L, Shani G, Shapira B, Schclar A (2013) Improving simple collaborative filtering models using ensemble methods. In: Multiple classifier systems. Lecture notes in computer science, vol\u00a07872. Springer, Heidelberg","DOI":"10.1007\/978-3-642-38067-9_1"},{"key":"92_CR36","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1021\/jm010520k","volume":"45","author":"J Xu","year":"2002","unstructured":"Xu J (2002) A new approach to finding natural chemical structure classes. J Med Chem 45:5311\u20135320","journal-title":"J Med Chem"},{"key":"92_CR37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11030-014-9543-5","volume":"18","author":"L Chen","year":"2014","unstructured":"Chen L, Wang L, Gu Q, Xu J (2014) An in silico protocol for identifying mTOR inhibitors from natural products. Mol Divers 18:841\u2013852","journal-title":"Mol Divers"},{"key":"92_CR38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/ml400378e","volume":"5","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Zhang X, Chen Y, Lu S, Peng Y, Wang X, Guo C, Zhou A, Zhang J, Luo Y, Shen Q, Ding J, Meng L, Zhang J (2014) Crystal structures of PI3kalpha complexed with PI103 and its derivatives: new directions for inhibitors design. ACS Med Chem Lett 5:138\u2013142","journal-title":"ACS Med Chem Lett"},{"key":"92_CR39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neulet.2010.06.084","volume":"482","author":"K Kuper","year":"2010","unstructured":"Kuper K, Heil M (2010) Letter search and relatedness proportion: further electrophysiological evidence for the automaticity of semantic activation. Neurosci Lett 482:26\u201330","journal-title":"Neurosci Lett"},{"key":"92_CR40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","volume":"497","author":"HJ Yang","year":"2013","unstructured":"Yang HJ, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP (2013) mTOR kinase structure, mechanism and regulation. Nature 497:217\u2013223","journal-title":"Nature"},{"key":"92_CR41","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/prot.21123","volume":"65","author":"V Hornak","year":"2006","unstructured":"Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65:712\u2013725","journal-title":"Proteins"},{"key":"92_CR42","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157\u20131174","journal-title":"J Comput Chem"},{"key":"92_CR43","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1021\/ci400322j","volume":"53","author":"L Wang","year":"2013","unstructured":"Wang L, Gu Q, Zheng X, Ye J, Liu Z, Li J, Hu X, Hagler A, Xu J (2013) Discovery of new selective human aldose reductase inhibitors through virtual screening multiple binding pocket conformations. J Chem Inf Model 53:2409\u20132422","journal-title":"J Chem Inf Model"},{"key":"92_CR44","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/wcms.1121","volume":"3","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer R, Case DA, Walker RC (2013) An overview of the Amber biomolecular simulation package. Comput Mol Sci 3:198\u2013210","journal-title":"Comput Mol Sci"},{"key":"92_CR45","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","volume":"33","author":"PA Kollman","year":"2000","unstructured":"Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE 3rd (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889\u2013897","journal-title":"Acc Chem Res"},{"key":"92_CR46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","volume":"51","author":"T Hou","year":"2011","unstructured":"Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51:69\u201382","journal-title":"J Chem Inf Model"},{"key":"92_CR47","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1021\/jp404160y","volume":"117","author":"L Xu","year":"2013","unstructured":"Xu L, Sun H, Li Y, Wang J, Hou T (2013) Assessing the performance of MM\/PBSA and MM\/GBSA methods. 3. The impact of force fields and ligand charge models. J Phys Chem B 117:8408\u20138421","journal-title":"J Phys Chem B"},{"key":"92_CR48","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcc.21666","volume":"32","author":"T Hou","year":"2011","unstructured":"Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the molecular mechanics\/Poisson Boltzmann surface area and molecular mechanics\/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. J Comput Chem 32:866\u2013877","journal-title":"J Comput Chem"},{"key":"92_CR49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.01259-13","volume":"58","author":"B Xu","year":"2014","unstructured":"Xu B, Wang L, Gonzalez-Molleda L, Wang Y, Xu J, Yuan Y (2014) Antiviral activity of (+)-rutamarin against Kaposi\u2019s sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II. Antimicrob Agents Chemother 58:563\u2013573","journal-title":"Antimicrob Agents Chemother"},{"key":"92_CR50","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.ejmech.2010.01.016","volume":"45","author":"S Sakkiah","year":"2010","unstructured":"Sakkiah S, Thangapandian S, John S, Kwon YJ, Lee KW (2010) 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Eur J Med Chem 45:2132\u20132140","journal-title":"Eur J Med Chem"},{"key":"92_CR51","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1021\/ci100511v","volume":"51","author":"W Zhao","year":"2011","unstructured":"Zhao W, Gu Q, Wang L, Ge H, Li J, Xu J (2011) Three-dimensional pharmacophore modeling of liver-X receptor agonists. J Chem Inf Model 51:2147\u20132155","journal-title":"J Chem Inf Model"},{"key":"92_CR52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","volume":"125","author":"ZA Knight","year":"2006","unstructured":"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733\u2013747","journal-title":"Cell"},{"key":"92_CR53","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/pro.2517","volume":"23","author":"P Chen","year":"2014","unstructured":"Chen P, Deng YL, Bergqvist S, Falk MD, Liu W, Timofeevski S, Brooun A (2014) Engineering of an isolated p110alpha subunit of PI3Kalpha permits crystallization and provides a platform for structure-based drug design. Protein Sci 23:1332\u20131340","journal-title":"Protein Sci"},{"key":"92_CR54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/ml400378e","volume":"5","author":"Y Zhao","year":"2014","unstructured":"Zhao Y (2014) Crystal structures of PI3K\u03b1 complexed with PI103. ACS Med Chem Lett 5:138\u2013142","journal-title":"ACS Med Chem Lett"},{"key":"92_CR55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5\u201329","journal-title":"CA Cancer J Clin"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10822-017-0092-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-017-0092-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-017-0092-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T08:26:44Z","timestamp":1603614404000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10822-017-0092-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,6]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["92"],"URL":"https:\/\/doi.org\/10.1007\/s10822-017-0092-8","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,6]]}}}